The Financial

Teva Announces FDA Approval of QVAR RediHaler Inhalation Aerosol

The FINANCIAL — Teva Pharmaceutical Industries Ltd. announced on August 7 that the U.S. Food and Drug Administration (FDA) has approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation ...
Healio

FDA approves QVAR RediHaler as maintenance therapy for asthma

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced that the FDA approved QVAR RediHaler inhalation aerosol for the prophylactic ...
Business Wire

Teva Announces U.S. Launch of QVAR ® RediHaler ™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol

First and Only Breath-Actuated Aerosol Inhaled Corticosteroid in the United States Designed to Help Eliminate the Need for Hand-Breath Coordination JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical ...
FiercePharma

QVAR® Versus Fluticasone in a Real-World Study Highlights the Importance of Inhaled Corticosteroid (ICS) Choice in Achieving Ast

Study reveals that patients treated with QVAR had a similar or better chance of achieving asthma control at lower prescribed doses than with fluticasone HORSHAM, Pa., Sept. 8 /PRNewswire/ -- Teva ...
FiercePharma

Teva Received FDA Approval for QVAR® (beclomethasone dipropionate HFA) with Dose Counter

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of QVAR® (beclomethasone dipropionate ...
Monthly Prescribing Reference

Breath-Actuated Qvar RediHaler Available for Asthma Maintenance Treatment

Qvar RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is a breath-actuated inhaled prescription medicine used as a maintenance treatment for the prevention and control of asthma in ...
Monthly Prescribing Reference

Breath-Actuated vs. Metered-Dose Inhaler for Beclomethasone Dipropionate Compared

A total of 425 patients were included in both the modified intention-to-treat and safety analyses. ATLANTA, GA—Findings of a Phase 3 study (NCT02513160) presented at the 2017 AAAAI Annual Meeting ...
EurekAlert!

QVAR real-world study to be presented at annual ATS International Conference

Jerusalem, May 18, 2014 – Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR® will be presented at the American ...
Morningstar

Berman Tabacco, Sperling Kenny Nachwalter, LLC and Hilliard Shadowen LLP Announce a Class Action Settlement If You Purchased, Paid For, or Provided Reimbursement for QVAR® and ...

Did You Purchase, Pay for, or Provide Reimbursement for QVAR® and/or QVAR RediHaler® Inhalers? You Could Get Money from a Settlement. There is a Settlement in a class action lawsuit with Teva ...
Nature

Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomized, controlled pilot study

The efficacy of inhaled steroids in spontaneously breathing infants with established bronchopulmonary dysplasia (BPD) is debatable. The inhaled steroid hydrofluoalkane-beclomethasone dipropionate ...
Pharmabiz

Ivax launches Qvar in Easi-Breathe inhaler in UK

Ivax Corporation has launched its asthma medicine Qvar in its patented Easi-Breathe inhaler in the United Kingdom. The product, approved on September 30, 2004, is being marketed by Ivax' UK subsidiary ...